13. Molecular biological features and ctDNA status of stage II-III colon cancer
Main Article Content
Abstract
A cross-sectional descriptive study was conducted involving 102 patients with stage II-III colorectal cancer treated at K Hospital and Nghe An Cancer Hospital. The study aimed to characterize the molecular biology features and circulating tumor DNA (ctDNA) status post-curative resection. The highest mutation rate was observed in the APC gene (64.7%), followed by TP53 (52.9%), KRAS (45.1%), PIK3CA (24.5%), and SMAD4 (16.67%). APC and TP53 mutations were predominantly located in the left colon, with statistically significant differences (p = 0.005 and p = 0.006, respectively). In contrast, SMAD4 mutations were more frequent in the right colon (p = 0.011). The postoperative ctDNA detection rate was 14.7%, and was significantly higher in poorly differentiated, mucinous, and signet-ring cell carcinoma subtypes (p = 0.042). Molecular characteristics and ctDNA status provide valuable insights for developing biomarkers to assist in diagnosis, treatment decision-making, and prognosis assessment in colorectal cancer patients.
Article Details
Keywords
Colon cancer, gene mutations, ctDNA, minimal residual disease
References
2. Osterman E, Hammarström K, Imam I, Osterlund E, Sjöblom T, Glimelius B. Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It? Cancers. Nov 9 2020; 12(11)doi:10.3390/cancers12113308.
3. Böckelman C, E. EB, Tuomas K, F. HT, and Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncologica. 2015/01/02 2015; 54(1): 5-16. doi:10.3109/0284186X.2014.975839.
4. Benhaim L, Bouché O, Normand C, et al. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). European journal of cancer (Oxford, England : 1990). Dec 2021; 159: 24-33. doi:10.1016/j.ejca.2021.09.004.
5. Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England Journal of Medicine. 2022; 386(24): 2261-2272. doi:doi:10.1056/NEJMoa2200075.
6. Đinh NT, Trịnh LH, Nguyễn LH. Kết quả điều trị bổ trợ ung thư đại tràng giai đoạn II, III bằng phác đồ mFOLFOX6 tại bệnh viện đa khoa tỉnh Ninh Bình. Tạp chí Y học Việt Nam. 10/17 2024; 543(2). doi:10.51298/vmj.v543i2.11392.
7. Minh Sơn Đ, Quốc Tuấn L, Văn Hiếu N. Tác dụng không mong muốn của hóa trị bổ trợ phác đồ XELOX trong điều trị ung thư đại tràng giai đoạn II, III tại Bệnh viện Đà Nẵng. Tạp chí Y học Việt Nam. 02/25 2022; 510(1). doi: 10.51298/vmj.v510i1.1936.
8. Haller DG, Tabernero J, Maroun J, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. Journal of Clinical Oncology. 2011; 29(11): 1465-1471. doi:10.1200/jco.2010.33.6297.
9. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology. Sep 2002; 123(3): 862-76. doi:10.1053/gast.2002.35392.
10. Van den Broek E, Krijgsman O, Sie D, et al. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. Oncotarget. Nov 8 2016; 7(45): 73876-73887. doi:10.18632/oncotarget.12510.
11. Li AJ, Li HG, Tang EJ, et al. PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients. World journal of gastroenterology. Feb 7 2018; 24(5): 631-640. doi:10.3748/wjg.v24.i5.631.
12. Ciepiela I, Szczepaniak M, Ciepiela P, et al. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients. Scientific Reports. 2024/02/26 2024; 14(1): 4619. doi:10.1038/s41598-024-55139-w.
13. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. The Clinical biochemist Reviews. May 2010; 31(2): 31-8.
14. Trọng Hòa N, Lê Huy T. Mối liên quan giữa tình trạng đột biến gen KRAS, NRAS, BRAF và một số đặc điểm bệnh học ung thư biểu mô đại trực tràng giai đoạn di căn. Tạp chí Y học Việt Nam. 10/18 2021; 506(1)doi: 10.51298/vmj.v506i1.1190.
15. Wasserman I, Lee LH, Ogino S, et al. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clinical cancer research : an official journal of the American Association for Cancer Research. Mar 15 2019; 25(6): 1948-1956. doi:10.1158/1078-0432.Ccr-18-1726.